Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Closure Medical (CLSR) fomerly Tri-Point Medical (TPMC) -- Ignore unavailable to you. Want to Upgrade?

To: Saban Kurucay who wrote (129)	3/22/1998 12:07:00 PM
From: David S.	Respond to of 184

re:internal use - current product cannot be used for that, in fact, in the fda approval, it says that the docs have to make sure that the product does not get inside the body. the product is basically "crazy glue" that has been modified for wound closure. Look at the ingredients.

To: Saban Kurucay who wrote (129)	3/22/1998 3:28:00 PM
From: JYatsu	Read Replies (1) \| Respond to of 184

I too am in the medical field. I would predict that some teaching hospitals will continue to use stitches, however if the rest come to use Dermabond that's a good chunk of the market. We need only to look at the Canadian experience where cost is more serious a driver of care, Dermabond is used routinely. Secondly I believe there is a whole untapped market in the aesthetic plastic surgeons. They have a corner of the market yet untapped. They operate in a sterile environment and in my estimation should take up using Dermabond where they are currently using small numerous stitches. Another factor not counted on by some is the shear size of the J&J/Ethicon sales force. I believe this huge sales force will be motivated by bonuses and other incentives to capitalize on their "first to market" advantage.